In this multicenter, randomized study, cytomegalovirus (CMV)-seropositive patients who received an allogeneic bone marrow transplant were provided high-dose intravenous acyclovir (500 mg/m 2 q8h) from the day of transplantation until engraftment. The patients were then randomly assigned to receive either oral valacyclovir, 2 g q.i. ). Oral P p .588 valacyclovir can be an effective alternative to intravenous ganciclovir for prophylaxis of CMV disease after bone marrow transplantation.
Patients undergoing allogeneic bone marrow transplantation are at great risk for cytomegalovirus (CMV) infection, which can cause considerable posttransplantation morbidity and mortality [1, 2] . Fortunately, as a result of effective prophylactic strategies, CMV disease can now be successfully prevented in most allogeneic bone marrow transplant (BMT) recipients [3] . For CMV-seropositive patients or CMV-seronegative patients with a CMV-seropositive donor, prophylaxis with ganciclovir is highly effective. Prophylactic strategies that use ganciclovir include the early initiation of preemptive ganciclovir therapy on the basis of a diagnosis of CMV antigenemia or PCR positive for CMV DNA, and universal ganciclovir prophylaxis initiated at the time of marrow engraftment and continued until day 100 after transplantation [4] [5] [6] [7] .
Despite its effectiveness, ganciclovir causes frequent dose-limiting neutropenia in BMT recipients. This drug-induced neutropenia has been associated with an increased incidence of bacteremia and invasive fungal infection as well as decreased survival rates [4, 7, 8] . In addition, because of the limited bioavailability of and the paucity of efficacy data for oral ganciclovir for BMT recipients, ganciclovir is usually administered intravenously through a central catheter [9, 10] . This increases both transplantation-related costs and the risk for line-related infections. Thus, safer and more convenient antiviral agents for CMV prophylaxis are needed.
Prophylaxis with high doses of either intravenous or oral acyclovir have been reported to reduce the risk of CMV disease after bone marrow transplantation [11, 12] . In contrast to ganciclovir, acyclovir is well tolerated, is not myelosuppressive, and may improve the overall survival rate among BMT recipients [11, 12] . Nevertheless, the efficacy of oral acyclovir for CMV prophylaxis has been limited by the drug's low oral bioavailability and the low in vitro susceptibility of CMV to acyclovir [13, 14] . Valacyclovir, the l-valyl ester of acyclovir, is rapidly converted to acyclovir after oral administration and has an oral bioavailability 3-5 times that of acyclovir [15] . Valacyclovir, at a dosage of 2 g q.i.d., results in total acyclovir exposure similar to that achieved with an intravenous acyclovir regimen of 10 mg/kg t.i.d., which is adequate to inhibit many clinical strains of CMV [14, 15] . For these reasons, we conducted a randomized, open-label study of oral valacyclovir and intravenous ganciclovir that compared their safety in patients and their effects on CMV disease and patient survival among allogeneic BMT recipients.
PATIENTS AND METHODS

Patients.
Patients were eligible for the study if they received an allogeneic BMT from a related or unrelated donor, were у13 years of age, and were seropositive for CMV antibody before transplantation. Patients were excluded from the study if they were undergoing a second bone marrow transplantation or a peripheral blood stem cell transplantation, or if they had renal insufficiency (creatinine clearance, !50 mL/min) or hepatic dysfunction (serum glutamic oxaloacetic transaminase or serum glutamic pyruvic transaminase levels of 13 times the upper limit of the range considered to be normal). Patients receiving antiviral drugs for possible or documented herpesvirus infection (except localized herpes simplex virus infection) and patients being treated with a CMV hyperimmunoglobulin were also excluded. The study was approved by the institutional review board at each study center, and informed consent was obtained from each patient or from a relative responsible for the patient.
Study design and administration of study drugs. On the day of transplantation, eligible patients were randomly assigned to receive either prophylactic oral valacyclovir or prophylactic intravenous ganciclovir. All patients initially received intravenous acyclovir therapy (500 mg/m 2 q8h) that started on the day of bone marrow transplantation and ended at the time of marrow engraftment (defined as 2 consecutive days with an absolute neutrophil count of у750 cells/mm 3 ). During the period from engraftment to day 100 after transplantation, patients in the valacyclovir group received oral valacyclovir, 2g q6h, and patients in the ganciclovir group received intravenous ganciclovir, 5 mg/kg iv q12h for 1 week, followed by 6 mg/kg once daily on 5 days of each week. The doses of intravenous acyclovir, oral valacyclovir, and intravenous ganciclovir were reduced for patients who developed renal failure [12, 16, 17] . Patients randomly assigned to receive oral valacyclovir could continue to receive intravenous acyclovir if they were unable to tolerate oral medications. If a documented, breakthrough herpesvirus disease developed while the patient was receiving the study drug, the study drug could be discontinued and another, appropriate antiviral therapy could be initiated.
Laboratory procedures. The CMV serological status of patients and bone marrow donors was determined by latex agglutination testing or EIA. Blood and urine samples for the detection of CMV in culture were obtained from patients before entry into the study, once weekly until day 100 after transplantation, and at the time of completion of the study drug regimen. During the time that this study was conducted, surveillance tests for CMV antigen or CMV DNA in the blood were not standard practice in the transplantation centers participating in this study and were not performed. Whenever appropriate, viral cultures of bronchoalveolar lavage samples, biopsy material, and samples from other suspected sites of infection were performed; shell vial culture and conventional tissue culture were used. Complete blood counts, serum creatinine level determinations, urinalyses, liver function studies (which measured the levels of serum glutamic oxaloacetic transaminase, serum glutamic pyruvic transaminase, alkaline phosphatase, and total serum bilirubin), and serum lactate dehydrogenase measurements were performed at the time of entry into the study, once or twice weekly until day 100 after transplantation, every 2 weeks between days 100 and 180 after transplantation, and after completion of the study drug regimen.
Isolates of CMV obtained from either surveillance or diagnostic cultures were tested for their susceptibility to acyclovir and ganciclovir. Virus susceptibility testing was performed in the clinical virology laboratory at Glaxo Wellcome (Research Triangle Park, NC) by a plaque reduction assay [18] . CMV strain AD169 (American Type Culture Collection) and 2 laboratory-generated acyclovir-resistant strains of CMV (mutants ACV R A and ACV R B) were used as controls. The mutant ACV R A carries a point mutation that encodes the amino acid substitution Met844Thr in the viral DNA polymerase (phenotype GCV R ACV R PFA R HPMPC S ). The mutant ACV R B carries a point mutation that encodes the amino acid substitution Leu802Met in the viral DNA polymerase (phenotype GCV S ACV R PFA S HPMPC S ). Definitions of viral infection and disease. Infection with CMV, herpes simplex virus, or varicella-zoster virus was defined as the isolation of the respective virus from cultures of blood, urine, or throat samples or cultures of samples obtained from a skin lesion or any other site. CMV pneumonia was diagnosed by demonstrating the presence of CMV in a bronchoalveolar lavage or lung tissue sample obtained from a patient with tachypnea, hypoxemia, fever, and interstitial pulmonary infiltrates on a chest radiograph, none of which were explainable by other causes. CMV disease of the gastrointestinal tract or liver was diagnosed on the basis of histological or culture evidence of CMV in a biopsy sample obtained from the gastrointestinal tract or liver of a patient with gastrointestinal symptoms or liver dysfunction not explainable by other causes. CMV syndrome was defined as persistent fever and wasting, with or without leukopenia and thrombocytopenia, which could not be attributed to other causes in a patient with CMV viremia or antigenemia. Other manifestations of CMV disease were diagnosed by demonstrating the presence of CMV by culture or by cytopathological analysis in samples from the organ site of a patient with clinical symptoms and signs of infection not explainable by other causes. Disease due to herpes simplex virus or varicella-zoster virus was defined as the growth of herpes simplex virus or varicella-zoster virus in a culture of samples obtained from a patient with symptomatic mucocutaneous lesions.
Study end points and statistical analysis. Study end points included the incidences of CMV infection and disease; survival; the incidence of other herpesvirus infection, bacterial infection, and fungal infection; and the incidence of neutropenia (defined as a decrease in the absolute neutrophil count to !750 cells/ mm 3 on 2 consecutive days after engraftment) and other drugrelated adverse events. Patients were followed for 6 months after transplantation or until the time of death. All patients were evaluated by intent-to-treat analysis to determine study drug efficacy; safety data were analyzed only for patients who received у1 dose of the study drug. Proportional hazard regression analysis, adjusting for site as a covariate, was used to calculate the between-treatment hazard ratios (HRs) and 95% CIs. The Kaplan-Meier product-limit method was used to plot the distribution of time to each end point [19] .
Determination of the sample size for the study was based on the efficacy end point of survival and used estimate considerations rather than statistical power. In a previous study of allogeneic BMT recipients, a 70% survival rate was associated with the use of high-dose intravenous acyclovir followed by oral acyclovir [12] . If the underlying survival population proportion is 0.70, then with a probability of 0.90, a sample size of 80 matched related patients per treatment group yielded a 95% CI with half-width of !0.115. The distribution of the 95% CI was based on Monte Carlo simulation.
RESULTS
Patient characteristics.
From September 1995 through June 1998, a total of 168 patients were enrolled in the study. Eightythree patients were randomized to receive oral valacyclovir, and 85 patients were randomized to receive intravenous ganciclovir. The 2 groups of patients were similar in terms of demographic characteristics (table 1) .
Study drug administration. As a result of early death, inability to take oral medication, or withdrawal from the study, 12 patients in the valacyclovir group and 19 patients in the ganciclovir group received only intravenous acyclovir. Thus, 71 patients received oral valacyclovir or intravenous acyclovir after engraftment (median duration of therapy, 65 days; range, 1-86 days), and 66 patients received intravenous ganciclovir after engraftment (median duration of therapy, 71 days; range, 3-87 days).
CMV infection and disease. Table 2 compares the incidences of CMV infection and disease within 180 days of transplantation in the 2 study groups. CMV infection occurred in 10 (12%) of 83 patients in the valacyclovir group and in 16 (19%) of 85 patients in the ganciclovir group. Blood and urine were the most common fluids (or sites) from which CMV was cultured. For 1 patient in the valacyclovir group, CMV was isolated from both blood cultures and culture of specimens obtained from a bronchoalveolar lavage, which was performed to evaluate pulmonary hemorrhage in the patient. This patient had no evidence of CMV pneumonia. The median time to onset of CMV infection was 47 days (range, 2-121 days) after transplantation in the valacyclovir group and 66 days (range, 2-152 days) after transplantation in the ganciclovir group (P p ). The Kaplan-Meier estimates for the probability of CMV .268 infection during the first 180 days after transplantation among patients in the valacyclovir and ganciclovir groups are shown in figure 1 ; there was no significant difference between the 2 study groups (HR, 1.042; 95% CI, 0.391-2.778;
). P p .934 There were 2 cases of CMV disease (in 2 [2%] of 83 patients) in the valacyclovir group and 1 case (in 1 [1%] of 85 patients) in the ganciclovir group. In the valacyclovir group, one patient developed CMV gastrointestinal disease on day 55 after transplantation, and a second patient experienced CMV cystitis on day 42 after transplantation. The only patient in the ganciclovir group who had CMV disease developed a CMV syndrome on day 180 after transplantation. Each patient with CMV disease was treated successfully with intravenous ganciclovir. There were no deaths attributable to CMV infection, and no cases of CMV interstitial pneumonia occurred in either study group. The Kaplan-Meier estimates of the probability of CMV disease occurring during the first 180 days after transplantation among patients in the valacyclovir and ganciclovir groups are shown in figure 2 ; there was no significant difference between the 2 study groups (HR, 1.943; 95% CI, 0.176-21.44;
). P p .588 Although the incidences of CMV infection and disease were similar in the valacyclovir and ganciclovir groups, more patients in the valacyclovir group underwent therapeutic interventions with alternative antiviral regimens. Administration of prophy- lactic oral valacyclovir was discontinued for 10 (12%) of 83 patients in the valacyclovir group, all of whom were then administered other antiviral therapies (8 patients received intravenous ganciclovir, 1 patient received intravenous foscarnet, and 1 patient received intravenous acyclovir), whereas doses of intravenous ganciclovir were increased for 3 (4%) of 85 patients in the ganciclovir group ( ). The indications for ther-P p .039 apeutic intervention in the valacyclovir group were documented CMV disease (diagnosed in 2 patients), documented asymptomatic CMV infection (3 patients), documented breakthrough genital herpes simplex virus infection (1 patient), and possible CMV infection (4 patients). The reasons for therapeutic inter- Other herpesvirus infections. Table 3 shows the incidence and types of infection due to herpes simplex virus and varicellazoster virus. Herpes simplex virus infection occurred in 3 (4%) of 83 patients in the valacyclovir group and in 4 (5%) of 85 patients in the ganciclovir group. Varicella-zoster infection developed in 2 patients (2%) in the valacyclovir group and in 1 patient (1%) in the ganciclovir group. Except for one case of genital herpes simplex virus infection that occurred on day 47 after transplantation and then recurred on day 87 after transplantation in the valacyclovir group, and except for one case of oral herpes simplex virus infection that occurred on day 73 after transplantation in the ganciclovir group, all infections occurred beyond day 100 after transplantation, when patients were no longer receiving the study drug. All of these infections resolved after appropriate antiviral treatment.
Susceptibility of virus isolates to study drugs. A total of 13 isolates of CMV (11 isolates from blood and 2 isolates from urine) recovered from 6 patients (4 patients in the valacyclovir group and 2 patients in the ganciclovir group) were available for determination of their in vitro susceptibilities to both ganciclovir and acyclovir. Three CMV isolates were recovered from the blood of one patient who was still receiving prophylactic intravenous ganciclovir, and 10 CMV isolates were obtained from the blood or urine of patients who already had completed prophylaxis and were no longer receiving the study drug. The mean IC 50 of ganciclovir ‫ע(‬ SD) for all the isolates was mM (range, 3.7-8.6 mM), compared with an IC 50 of 5.9 ‫ע‬ 1.4 6.1 mM for the control strain AD169. Except for one CMV isolate with a ganciclovir IC 50 of 8.6 mM, all the clinical CMV isolates had a ganciclovir IC 50 of р7.1 mM. The mean IC 50 of acyclovir ‫ע(‬ SD) for all the isolates was mM (range, 209 ‫ע‬ 80 111-432 mM), compared with an IC 50 of 123 mM for control strain AD169 and ICs 50 of 665 and 11000 mM for 2 acyclovirresistant strains of CMV. Except for one CMV isolate with an acyclovir IC 50 of 432 mM, all the clinical CMV isolates had an acyclovir IC 50 of р252 mM. None of the CMV isolates that were tested for in vitro susceptibility to ganciclovir and acyclovir were associated with CMV disease. In the 3 patients from whom multiple CMV isolates were recovered at different times after transplantation, there were no significant increases in either the ganciclovir IC 50 or acyclovir IC 50 over time.
Bacterial infection, fungal infection, and septicemia. Before engraftment, when all patients were neutropenic (defined as an absolute neutrophil count of !750 cells/mm 3 ) and were not yet receiving the study drug, the incidences of bacterial infection (51% in the valacyclovir group and 45% in the ganciclovir group), Candida or Aspergillus infection (14% in the valacyclovir group and 12% in the ganciclovir group), and septicemia (41% in the valacyclovir group and 34% in the ganciclovir group) were similar in each study group. After engraftment, when patients were receiving the study drug, the incidences of bacterial infection (32% in the valacyclovir group and 41% in the ganciclovir group), Candida or Aspergillus infection (10% in the valacyclovir group and 18% in the gan- Figure 2 . Kaplan-Meier product-limit estimates of survival distributions of time to the development of cytomegalovirus (CMV) disease in patients receiving oral valacyclovir and intravenous ganciclovir (P p ). .588 Table 3 . Incidence and types of other herpesvirus infections that occurred among study group participants within 180 days after transplantation. NOTE. Data are no. of patients, unless otherwise indicated. All infections occurred 1100 days after transplantation and after administration of the study drug was stopped, except for 2 cases of herpes simplex virus infection, 1 of which occurred in the valacyclovir group on day 47 after transplantation and 1 of which occurred in the ganciclovir group on day 73 after transplantation. ciclovir group), and septicemia (17% in the valacyclovir group and 26% in the ganciclovir group) were higher in the ganciclovir group. However, none of these differences was significant ( ).
Survival. Thirty-nine (47%) of 83 patients in the valacyclovir group and 31 (36%) of 85 patients in the ganciclovir group died as a result of complications that occurred within 180 days after transplantation. The causes of death were similar in both study groups (table 4). Bacterial and fungal infection, graft-versus-host disease, and multiorgan toxicity from chemoradiotherapy were the most common causes of death. There were no deaths due to viral infection. The Kaplan-Meier estimates of the probability of survival during the first 180 days after transplantation among patients in the valacyclovir group (55%) and patients in the ganciclovir group (64%) are shown in figure 3 . The difference in survival rate between the 2 groups was not significant (HR, 1.193; 95% CI, 0.739-1.925; P p ). .470
Adverse events. Adverse events attributed by investigators to the study drugs are summarized in table 5. Twenty-nine (41%) of 71 patients who received oral valacyclovir and 30 (45%) of 66 patients who received intravenous ganciclovir had adverse events that were probably or possibly related to the study drug. Neutropenia was the most frequent adverse event attributed by investigators to the study drugs, and it occurred less frequently in patients in the valacyclovir group (13%) than in patients in the ganciclovir group (32%) ( ). The P p .007 range of the absolute neutrophil count among these patients was 7-324 cells/mm 3 . The incidences of other types of adverse events were similar in the 2 groups of patients. One case of thrombotic thrombocytopenia purpura related to the study drug occurred in a patient receiving oral valacyclovir and cyclosporine. Of 2 patients randomized to receive ganciclovir, 1 also developed thrombotic thrombocytopenic purpura and 1 developed hemolytic uremic syndrome. However, both of these cases were attributed to cyclosporine rather than to intravenous ganciclovir.
Although more cases of neutropenia were attributed by investigators to intravenous ganciclovir than were attributed to oral valacyclovir, the number of patients with protocol-defined neutropenia was similar in the 2 study groups. A total of 27 patients in the valacyclovir group and 22 patients in the ganciclovir group had a decrease in the absolute neutrophil count to !750 cells/mm 3 ; 12 patients in the valacyclovir group and 16 patients in the ganciclovir group had a decrease to !500 cells/mm 3 ; and 7 patients in the valacyclovir group and 6 patients in the ganciclovir group had a decrease to !250 cells/ mm 3 . Among patients with neutropenia associated with use of the study drugs, more patients in the ganciclovir group (15 patients), compared with patients in the valacyclovir group (2 patients) had their study drug therapy stopped temporarily or had the dose of the study drug reduced because of the neutropenia ( ). Hematopoietic growth factors (e.g., gran-P p .001 ulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor) were used for 17 patients in the ganciclovir group and for 16 patients in the valacyclovir group upon engraftment, but the mean number of days of growth factor use per patient was greater for patients in the ganciclovir Table 4 . Causes of death among study group participants who died within 180 days after transplantation. 
NOTE.
GVHD, graft-versus-host disease; HUS, hemolytic uremic syndrome; IIP, idiopathic interstitial pneumonia; TTP, thrombotic thrombocytopenia purpura.
a Thirty-nine (47%) of 83 patients died. b Thirty-one (36%) of 85 patients died. Figure 3 . Kaplan-Meier estimates of survival probability among patients receiving oral valacyclovir and intravenous ganciclovir ( ). P p .470 group (12.6 days; range, 1-78 days) than for patients in the valacyclovir group (5.1 days; range, 1-14 days) ( ). P p .186
DISCUSSION
In this study, oral valacyclovir and intravenous ganciclovir had similar efficacies for prevention of CMV disease in allogeneic BMT recipients. There were only 2 cases of CMV disease in the valacyclovir group and 1 case in the ganciclovir group (table  2) . No cases of CMV pneumonia occurred in either study group. Furthermore, the incidences of herpes simplex virus infection (4% in the valacyclovir group and 5% in the ganciclovir group) and varicella-zoster virus infection (2% in the valacyclovir group and 1% in the ganciclovir group) were low in both study groups.
In a previous study of CMV prophylaxis after allogeneic bone marrow transplantation, the use of high-dose intravenous acyclovir followed by oral acyclovir was associated with an 8% incidence of CMV disease [12] . Similarly, in a recent study of valacyclovir therapy for prevention of CMV disease after renal transplantation, there was a 6% incidence of CMV disease among patients receiving valacyclovir [16] . The 2% incidence of CMV disease among the patients in the valacyclovir group in this study was lower than the incidence in these other studies. If the actual incidence of CMV disease with valacyclovir prophylaxis is 5% or 10%, the probabilities of observing CMV disease in р2 patients in a sample size of 83 patients are .209 and .008, respectively.
Two previous controlled studies found improved survival as well as decreased incidence of CMV disease in allogeneic BMT recipients receiving either intravenous acyclovir from 5 days before to 30 days after transplantation or intravenous acyclovir for 1 month followed by high-dose oral acyclovir for 6 months, compared with control patients receiving no prophylaxis or only low-dose acyclovir [11, 12] . This improved survival rate could not be confirmed with oral valacyclovir during this study. The survival rate was 53% among patients in the valacyclovir group, which was lower than the 70% survival rate previously reported with high-dose acyclovir [11, 12] . However, another, more recent study of the effect of high-dose acyclovir on survival after allogeneic bone marrow transplantation reported a survival probability of only 50% [20] , which is similar to the survival rate in the valacyclovir group in this trial. Differences in risk factors (e.g., age, underlying disease, type of transplant, HLA matching, conditioning regimen, and severity of graftversus-host disease) make it difficult to compare survival rates among different studies. In contrast to the present trial and the other recent study [20] , earlier studies showing a survival benefit associated with the use of high-dose acyclovir included mainly low-risk patients (i.e., patients who were younger in age, had HLA-matched donors, and had less severe graft-versushost disease). Finally, the lower-than-expected survival rate (53% compared with 70%) in a study sample size of only 168 patients contributed to a larger-than-predicted half-width of the 95% CI and a reduction in the statistical strength of the Table 5 . Adverse events related to study drug among study group participants. study for the evaluation of the effects of the study drugs on survival.
The most common adverse event that limits the effectiveness of ganciclovir is neutropenia, which may occur in 30%-58% of BMT recipients receiving prophylactic ganciclovir after engraftment [6] [7] [8] . This neutropenia may increase the risk for bacterial and fungal infections. In this study, the overall incidence of neutropenia was similar in the valacyclovir group and the ganciclovir group. However, more patients in the ganciclovir group had their prophylaxis with the study drug altered or stopped as a result of neutropenia, and they required a greater amount of hematopoietic growth factor. This more frequent discontinuation of intravenous ganciclovir therapy and greater usage of hematopoietic growth factor for patients receiving intravenous ganciclovir likely blunted the severity of neutropenia in these patients and, thus, made it more difficult to show a greater difference in the incidence of neutropenia among patients receiving intravenous ganciclovir and that among patients receiving oral valacyclovir. The incidences of bacterial infection, Candida or Aspergillus infection, or septicemia during administration of the study drug were also higher in the ganciclovir group, although these incidences were not statistically different from those in the valacyclovir group.
The oral valacyclovir in this study was generally well tolerated. Previous reports of neutropenia related to acyclovir or valacyclovir have been extremely rare [15, 21, 22] , and neutropenia has not been considered a significant adverse event associated with the use of either drug. In a study of valacyclovir prophylaxis for patients with HIV infection, valacyclovir appeared to be associated with moderate nephrotoxicity and an increased incidence of thrombotic microangiopathy-like syndromes [23] . The incidence of possible drug-related nephrotoxicity among patients in the valacyclovir group in this study of BMT recipients was low (10%) and was not significantly different from the 6% incidence among ganciclovir recipients. There was one case of nonfatal thrombotic thrombocytopenia purpura attributed to valacyclovir (table 5) . In contrast, in the ganciclovir group, 1 patient died of thrombotic thrombocytopenia purpura and 1 patient died of hemolytic uremic syndrome, and both diseases were attributed to cyclosporine. Nephrotoxicity and thrombotic microangiopathy-like events also were not associated with the use of prophylactic valacyclovir for renal transplant recipients [16] .
A limitation of this trial was the lack of blinding with respect to study drug assignment. Consequently, despite well-defined prestudy criteria for evaluating treatment response and adverse events, evaluation of the treatment response and the causes of adverse events, such as neutropenia, could have been somewhat biased. Nevertheless, the more frequent attribution by investigators of neutropenic events to ganciclovir and subsequent modification of ganciclovir prophylaxis are consistent with the results of previous blinded trials of prophylactic ganciclovir [6, 7] . Moreover, the results from this trial and other studies demonstrate that effective CMV prophylaxis with either intravenous acyclovir or oral valacyclovir can be safely continued for neutropenic patients for whom ganciclovir therapy is unsuitable [11, 12] .
A potential risk associated with the use of antiviral agents for prophylaxis is the emergence of resistant viruses. This problem has been observed mostly in patients with HIV infection, in whom ganciclovir-resistant CMV infection and acyclovirresistant herpes simplex virus infection have been associated with both prophylactic and therapeutic failures [24] [25] [26] . In contrast, the incidence of infection caused by drug-resistant CMV in bone marrow or solid-organ transplant recipients is low and may be related to the use of antiviral agents for more limited periods [27] [28] [29] [30] . None of the CMV isolates that were tested for in vitro susceptibility to ganciclovir and were associated with breakthrough infection in this study were resistant to ganciclovir. Furthermore, the 3 patients who developed CMV disease after receiving oral valacyclovir (2 patients) or intravenous ganciclovir (1 patient) prophylaxis were all treated successfully with therapeutic doses of intravenous ganciclovir.
In summary, the efficacy and safety of valacyclovir for prevention of CMV disease, which was demonstrated in this study as well as in a previous study of renal transplant recipients [16] , suggests that oral valacyclovir is an acceptable alternative to intravenous ganciclovir for CMV prophylaxis. Patients who are intolerant of ganciclovir as a result of neutropenia or a lack of adequate intravenous access may especially benefit from oral valacyclovir.
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